The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
The question is not just substitution but how SC therapeutics integration will affect health care delivery at scale. The real question is can we afford to ignore a more efficient, patient-centered ...
Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...
Subcutaneous Opdivo showed similar efficacy and safety to intravenous Opdivo in advanced ccRCC, with a slightly higher overall response rate. The CheckMate-67T trial confirmed pharmacokinetic and ...
This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
Hosted on MSN
Tumor formation's two-step process: Mutated cells can persist for long periods without turning cancerous
Researchers at City of Hope have found that cell mutations are necessary but not always sufficient for tumors to form. Instead, they suggest that additional risk factors that promote tumor growth, ...
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency? The following represents disclosure information provided by authors of this manuscript. All relationships ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results